MicroRNA and renal fibrosis in autosomal dominant polycystic kidney disease: a longitudinal study

被引:0
|
作者
Lai, Silvia [1 ]
Mastroluca, Daniela [1 ]
Perrotta, Adolfo Marco [1 ]
Muscaritoli, Maurizio [2 ]
Lucciola, Sara [3 ]
Felli, Maria Pia [4 ]
Izzo, Paolo [5 ]
Rotondi, Silverio [1 ]
Izzo, Sara [6 ]
Tartaglione, Lida [1 ]
Belli, Roberta [2 ]
Ramaccini, Cesarina [2 ]
Izzo, Luciano [5 ]
De Intinis, Claudia [5 ]
Panebianco, Valeria [3 ]
Mazzaferro, Sandro [1 ]
机构
[1] Sapienza Univ Rome, Dept Translat & Precis Med, Nephrol Unit, Rome, Italy
[2] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy
[3] Sapienza Univ Rome, Dept Radiol Sci Oncol & Pathol, Rome, Italy
[4] Sapienza Univ Rome, Dept Expt Med, Rome, Italy
[5] Sapienza Univ Rome, Dept Surg, Pietro Valdoni, Policlin Umberto 1, Rome, Italy
[6] Univ Campania Luigi Vanvitelli, Multidisciplinary Dept Med Surg & Dent Specialties, Plast Surg Unit, Naples, Italy
关键词
Autosomal dominant polycystic kidney disease; Total fibrotic volume; Plasma aldosterone; Subclinical atherosclerosis parameters; MODIFIER GENES; PROGRESSION; MODEL;
D O I
10.1007/s40620-024-01965-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary kidney disorder that may progress to kidney failure, accounting for 5-10% of all patients with end-stage kidney disease (ESKD). Clinical data, as well as molecular genetics and advanced imaging techniques have provided surrogate prognostic biomarkers to predict rapid decline in kidney function, nonetheless enhanced tools for assessing prognosis for ADPKD are still needed. The aim of this study was to analyze specific microRNAs involved in the pathogenesis of ADPKD and in the development of renal fibrosis, evaluating their potential role as predictors of renal function loss. Methods We evaluated kidney function by estimated glomerular filtration rate (eGFR) in 32 ADPKD patients in different stages of kidney disease at T0 and after a 24-month follow up (T1). Patients were divided into two groups: Rapid disease progression ([RP], n 15) and Non-rapid disease progression ([NRP], n 17), according to the Mayo Clinic classification criteria. At T0, ADPKD patients underwent plasma sampling for quantitative analysis of h-miR-17-5p, h-miR-21-5p and h-miR-199a-5p microRNA expression, using the quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) method and a 3 T magnetic resonance imaging (MRI), using an advanced MRI imaging protocol, for the quantification of total kidney volume (TKV), total perfusion volume (TPV) and total fibrotic volume (TFV). Results The expression of h-miR17-5p was higher (p < 0.05) in ADPKD patients with rapid disease progression. h-miR-17-5p, h-miR-21-5p and h-mir-199-5p showed a positive and significant correlation with the eGFR slope (mL/min/1.73 m(2)/year) (p < 0.05) but not with the eGFR at both T0 and T1. Both total fibrotic volume (cm(3)) and height-adjusted total fibrotic volume (cm(3)/m) were positively and significantly correlated to h-miR 21-5p and h-miR 199-5p (p < 0.05), but not to total kidney volume (cm(3)) and height-adjusted total kidney volume (cm(3)/m). Conclusions The microRNAs we studied were associated with fibrosis and renal damage, suggesting their possible role as biomarkers able to identify ADPKD patients at high risk of disease progression regardless of the degree of kidney function, and therefore suitable for medical therapy, and may help uncovering new molecular mechanisms underlying cystogenesis.
引用
收藏
页码:153 / 162
页数:10
相关论文
共 50 条
  • [31] Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease
    O'Sullivan, DA
    Torres, VE
    Gabow, PA
    Thibodeau, SN
    King, BF
    Bergstralh, EJ
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (06) : 976 - 983
  • [32] Autosomal dominant polycystic kidney disease
    Simms, Roslyn J.
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 352
  • [33] Autosomal dominant polycystic kidney disease
    Chow, Chern Li
    Ong, Albert C. M.
    CLINICAL MEDICINE, 2009, 9 (03) : 278 - 283
  • [34] Autosomal dominant polycystic kidney disease
    Lanktree, Matthew B.
    Chapman, Arlene B.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2017, 189 (45) : E1396 - E1396
  • [35] AUTOSOMAL DOMINANT POLYCYSTIC DISEASE OF THE KIDNEY
    FICK, G
    WEBER, M
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1992, 117 (30) : 1160 - 1164
  • [36] Autosomal Dominant Polycystic Kidney Disease
    Zacharia, George Sarin
    Rajakumari, P. K.
    JOURNAL OF PIONEERING MEDICAL SCIENCES, 2013, 3 (04): : 194 - 195
  • [37] Autosomal dominant polycystic kidney disease
    Silverman, Jonathan
    Desai, Chaitanya
    Lerma, Edgar V.
    DM DISEASE-A-MONTH, 2015, 61 (10): : 442 - 447
  • [38] AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    Pljesa, Steva
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2008, 136 : 340 - 347
  • [39] Autosomal dominant polycystic kidney disease
    Ferrer, Elisa
    Bozzo, Jordi
    DRUGS OF THE FUTURE, 2006, 31 (07) : 611 - 615
  • [40] Autosomal Dominant Polycystic Kidney Disease
    Perumareddi, Parvathi
    Trelka, Darin P.
    PRIMARY CARE, 2020, 47 (04): : 673 - 689